Introduction In recent months, several major biopharma companies have dramatically scaled back or outright halted their gene and cell therapy programs. This trend—highlighted by Biogen's decision to discontinue all adeno-associated virus (AAV) gene therapy research and Takeda's move to exit the cell therapy field—

Introduction Bristol Myers Squibb (BMS) and Takeda have recently joined forces with several peers in an ambitious data-sharing venture to advance artificial intelligence (AI) in drug discovery according to Reuters. Alongside AbbVie, Johnson & Johnson (J&J), and Astex Pharmaceuticals, they will pool proprietary research data -- specifically, thousands

Executive Overview Pharmaceutical royalties occupy a complex regulatory landscape where classification depends fundamentally on structure rather than asset type. As of October 2025, no jurisdiction treats pharmaceutical royalties as a distinct regulated asset class. Instead, regulatory treatment hinges on whether royalties are packaged as direct bilateral contracts (typically outside securities

Complete Biotech Deals Report: September 29-October 5, 2025 Executive Summary The week of September 29-October 5, 2025, witnessed 19 distinct biotechnology transactions with total disclosed deal value exceeding $11.5 billion. This comprehensive analysis covers all major biotech news sources, press releases, and SEC filings, revealing a week

Introduction: The Promise of Invisible Assets In the modern economy, the most valuable assets often cannot be seen or touched. Intellectual property—patents, trademarks, copyrights, and proprietary technologies—now comprises an estimated 70-80% of a typical firm's value, yet these intangible assets traditionally don't appear

Investment Thesis and Business Strategy Ligand Pharmaceuticals operates a "royalty aggregation" business model, building a diversified portfolio of drug royalty interests and licensing assets. The investment thesis is that Ligand can generate stable cash flows from marketed products while maintaining upside from a broad pipeline of partnered drug

Congratulations to Kumquat Biosciences on its brilliant naming -- the kumquat is indeed a great fruit, known for its sweet-tart flavor and auspicious connotations. But beyond the playful name, Kumquat Biosciences (a privately held San Diego-based biotech founded in 2019) has quickly grown into a serious player in the

Executive Summary: CVR deployment reaches $35 billion across Q1-Q3 2025 transactions Contingent Value Rights (CVRs) have become integral to biotech M&A structuring, with deployment across $35 billion in transaction value through Q3 2025. Data indicates CVR inclusion in 29% of life sciences acquisitions, representing a structural shift

In a high-interest-rate environment (U.S. Fed Funds ~5.25–5.50% in 2024), traditional biotech funding has pulled back sharply (VC investment in life sciences fell ~60% from 2021 peaks) while royalty financing has surged ~45% annually. The appeal is clear: royalty deals offer non-dilutive capital

The AI drug discovery sector achieved its first major clinical validation in 2025 with Insilico Medicine's rentosertib becoming the first fully AI-discovered and designed drug to demonstrate positive Phase IIa results, marking a significant development for the industry. This breakthrough, published in Nature Medicine in June 2025,